Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy
- 1 October 2002
- journal article
- research article
- Published by Elsevier in Neuromuscular Disorders
- Vol. 12, S71-S77
- https://doi.org/10.1016/s0960-8966(02)00086-x
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Novel mechanisms for antisense-mediated regulation of gene expressionBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 1999
- Antisense oligonucleotides as therapeutic agentsJournal of Cellular Physiology, 1999
- Implications of maturation for viral gene delivery to skeletal muscleNeuromuscular Disorders, 1998
- Membrane organization of the dystrophin-glycoprotein complexCell, 1991
- Surveying Cis-Acting Sequences of Pre-mRNA by Adding Antisense 2′-O-Methyl Oligoribonucleotides to a Splicing Reaction1The Journal of Biochemistry, 1990
- The Molecular Basis of Muscular Dystrophy in the mdx Mouse: a Point MutationScience, 1989
- The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscleNature, 1988
- The complete sequence of dystrophin predicts a rod-shaped cytoskeletal proteinCell, 1988
- An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locusGenomics, 1988
- Dystrophin: The protein product of the duchenne muscular dystrophy locusCell, 1987